Articles: PDF OnlyPharmacotherapy of Post-Traumatic Stress DisorderHamner, Mark B. M.D.; Labbate, Lawrence A. M.D. Author Information CME article by Mark B. Hamner, M.D., Associate Professor, and Lawrence A. Labbate, M.D., Associate Professor, Medical University of South Carolina and VA Medical Center, Charleston, SC Dr. Hamner has disclosed that he receives grant/research support from Bristol-Myers Squibb, Otsuka, Janssen, Wyeth-Ayerst, and Eli Lilly; and that he is a consultant to and/or on the speakers' bureau of Abbott, AstraZeneca, Janssen, Forest, and GlaxoSmithKline. Dr. Labbate has disclosed that he receives grant/research support from Eli Lilly and is on the speakers' bureau of Pfizer, Forest, and GlaxoSmithKline. The authors also have disclosed that of the drugs discussed in this article, only sertraline and paroxetine have been approved by the U.S. Food and Drug Administration for the treatment of post-traumatic stress disorder. International Drug Therapy Newsletter: May 2002 - Volume 37 - Issue 5 - p 33-39 Buy Abstract Learning Objectives: After reading this article, the practitioner should be able to: Describe the frequent psychiatric comorbidities that accompany and require treatment in post-traumatic stress disorder (PTSD). Cite the evidence supporting use of selective serotonin reuptake inhibitors (SSRIs) for the treatment of PTSD and the magnitude of benefit of SSRI treatment. Discuss the extent of the evidence for other agents, including anticonvulsants, benzodiazepines, and newer antipsychotics. © 2002 Lippincott Williams & Wilkins, Inc.